Cxcl13 antagonists and their use for the treatment of...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 39/395 (2006.01) A61K 31/7088 (2006.01) A61P 11/00 (2006.01)

Patent

CA 2682666

Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNF.alpha. antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.

L'invention concerne des procédés de traitement de troubles liés à l'activité de CXCL13 utilisant des antagonistes de CXCL13 et, facultativement, des antagonistes de TNFa, tels que des anticorps, y compris des portions ou variantes spécifiées, des polypeptides, des polynucléotides, de l'ARNsi, de l'ARNsh, des ribozymes et des ADNsymes. Des troubles liés à l'activité du CXCL13 comprennent des troubles inflammatoires, tels que des troubles pulmonaires, par exemple l'asthme, l'emphysème, et COPD, et le lupus érythémateux disséminé.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Cxcl13 antagonists and their use for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cxcl13 antagonists and their use for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cxcl13 antagonists and their use for the treatment of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1692214

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.